Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center

home / authors / jared-weiss-md-unc-lineberger-comprehensive-cancer-center

Articles

Next Steps for RET-Mutated Medullary Thyroid Cancer

Next Steps for RET-Mutated Medullary Thyroid Cancer

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Recent Approval of Selpercatinib in RET-Mutated MTC

Recent Approval of Selpercatinib in RET-Mutated MTC

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Multikinase TKIs in Medullary Thyroid Cancer

Multikinase TKIs in Medullary Thyroid Cancer

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Actionable Driver Mutations in Medullary Thyroid Cancer

Actionable Driver Mutations in Medullary Thyroid Cancer

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Epidemiology of Medullary Thyroid Cancer

Epidemiology of Medullary Thyroid Cancer

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Next Steps for RET Fusion+ NSCLC

Next Steps for RET Fusion+ NSCLC

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

RET Fusion+ NSCLC and COVID-19

RET Fusion+ NSCLC and COVID-19

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Intracranial Response Rates from RET Inhibitors

Intracranial Response Rates from RET Inhibitors

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Importance of Frontline RET Inhibition in NSCLC

Importance of Frontline RET Inhibition in NSCLC

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

FDA Approval of RET Inhibitors in NSCLC

FDA Approval of RET Inhibitors in NSCLC

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Best Practices for NGS Selection in NSCLC

Best Practices for NGS Selection in NSCLC

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Use of Liquid Biopsy for RET Detection

Use of Liquid Biopsy for RET Detection

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Optimal Detection of RET Fusions

Optimal Detection of RET Fusions

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Multikinase TKIs for RET Fusion+ NSCLC

Multikinase TKIs for RET Fusion+ NSCLC

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Biology of RET Genetic Alterations

Biology of RET Genetic Alterations

Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center;Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
November 16th 2020

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC